In case of NSCLC treatments, wild-type EGFR NSCLC patients also have low response to EGFR-TKI (tyrosine kinase inhibitors) treatment due to EGFR-TKIs are mostly effective in NSCLC harboring EGFR activating mutations [48]. Here, EGFR is linked to non-small cell lung carcinoma.